{"title":"体重指数和血清白蛋白作为小细胞肺癌营养状况指标的预后意义。","authors":"Faruk Tas, Akın Ozturk, Kayhan Erturk","doi":"10.1080/00325481.2024.2328512","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Body mass index (BMI) and serum albumin (ALB) level are long-established markers that reflect the nutritional status and eventually the prognosis of cancer patients. The objective of the study was to determine the clinical significance of these factors and specify their roles in outcomes compared with performance status (PS) and weight loss (WL), which are considered the most significant patient-related prognostic factors in small cell lung cancer (SCLC) treated with platinum-etoposide-based chemotherapy.</p><p><strong>Methods: </strong>A total of 378 patients with SCLC were enrolled in the study and analyzed retrospectively.</p><p><strong>Results: </strong>BMI values were similar by clinical stage, whereas the percentages of the patients with WL, low serum ALB, and particularly poor (≥2) PS were significantly higher in patients with extended disease SCLC (ED-SCLC) compared to those with limited disease SCLC (LD-SCLC). In LD-SCLC, patients with poor PS lived for a significantly shorter time than patients with good PS (HR: 7.791, <i>p</i> = 0.0001); however, BMI (HR: 1.035, <i>p</i> = 0.8), WL (HR: 0.857, <i>p</i> = 0.5), and ALB (HR: 0.743, <i>p</i> = 0.3) had no significant effect on the outcome. In ED-SCLC, PS (HR: 4.257, <i>p</i> = 0.0001), WL (HR: 1.677, <i>p</i> = 0.001), and ALB (HR: 0.680, <i>p</i> = 0.007) had an impact on survival, but BMI did not (HR: 0.791, <i>p</i> = 0.08). In LD-SCLC, the univariate analysis showed that only poor PS was correlated with increased mortality (HR: 7.791, <i>p</i> = 0.0001); yet it lost significance in multivariate analysis. In ED-SCLC, poor PS (HR: 4.257, <i>p</i> = 0.0001), WL (HR: 1.667, <i>p</i> = 0.001), and a low ALB level (HR: 0.680, <i>p</i> = 0.007) were shown to be factors for poor prognosis in the univariate analysis; yet only PS remained significant in multivariate analysis (HR: 2.286, <i>p</i> = 0.001).</p><p><strong>Conclusion: </strong>Even though BMI and serum albumin showed no prognostic value in SCLC patients treated with chemotherapy, PS was found to be the most significant prognostic factor in both LD- and ED-SCLC stages.</p>","PeriodicalId":94176,"journal":{"name":"Postgraduate medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prognostic significance of body mass index and serum albumin as the indicators of nutritional status in small cell lung cancer.\",\"authors\":\"Faruk Tas, Akın Ozturk, Kayhan Erturk\",\"doi\":\"10.1080/00325481.2024.2328512\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Body mass index (BMI) and serum albumin (ALB) level are long-established markers that reflect the nutritional status and eventually the prognosis of cancer patients. The objective of the study was to determine the clinical significance of these factors and specify their roles in outcomes compared with performance status (PS) and weight loss (WL), which are considered the most significant patient-related prognostic factors in small cell lung cancer (SCLC) treated with platinum-etoposide-based chemotherapy.</p><p><strong>Methods: </strong>A total of 378 patients with SCLC were enrolled in the study and analyzed retrospectively.</p><p><strong>Results: </strong>BMI values were similar by clinical stage, whereas the percentages of the patients with WL, low serum ALB, and particularly poor (≥2) PS were significantly higher in patients with extended disease SCLC (ED-SCLC) compared to those with limited disease SCLC (LD-SCLC). In LD-SCLC, patients with poor PS lived for a significantly shorter time than patients with good PS (HR: 7.791, <i>p</i> = 0.0001); however, BMI (HR: 1.035, <i>p</i> = 0.8), WL (HR: 0.857, <i>p</i> = 0.5), and ALB (HR: 0.743, <i>p</i> = 0.3) had no significant effect on the outcome. In ED-SCLC, PS (HR: 4.257, <i>p</i> = 0.0001), WL (HR: 1.677, <i>p</i> = 0.001), and ALB (HR: 0.680, <i>p</i> = 0.007) had an impact on survival, but BMI did not (HR: 0.791, <i>p</i> = 0.08). In LD-SCLC, the univariate analysis showed that only poor PS was correlated with increased mortality (HR: 7.791, <i>p</i> = 0.0001); yet it lost significance in multivariate analysis. In ED-SCLC, poor PS (HR: 4.257, <i>p</i> = 0.0001), WL (HR: 1.667, <i>p</i> = 0.001), and a low ALB level (HR: 0.680, <i>p</i> = 0.007) were shown to be factors for poor prognosis in the univariate analysis; yet only PS remained significant in multivariate analysis (HR: 2.286, <i>p</i> = 0.001).</p><p><strong>Conclusion: </strong>Even though BMI and serum albumin showed no prognostic value in SCLC patients treated with chemotherapy, PS was found to be the most significant prognostic factor in both LD- and ED-SCLC stages.</p>\",\"PeriodicalId\":94176,\"journal\":{\"name\":\"Postgraduate medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Postgraduate medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/00325481.2024.2328512\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/3/12 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Postgraduate medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/00325481.2024.2328512","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/12 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
Prognostic significance of body mass index and serum albumin as the indicators of nutritional status in small cell lung cancer.
Background: Body mass index (BMI) and serum albumin (ALB) level are long-established markers that reflect the nutritional status and eventually the prognosis of cancer patients. The objective of the study was to determine the clinical significance of these factors and specify their roles in outcomes compared with performance status (PS) and weight loss (WL), which are considered the most significant patient-related prognostic factors in small cell lung cancer (SCLC) treated with platinum-etoposide-based chemotherapy.
Methods: A total of 378 patients with SCLC were enrolled in the study and analyzed retrospectively.
Results: BMI values were similar by clinical stage, whereas the percentages of the patients with WL, low serum ALB, and particularly poor (≥2) PS were significantly higher in patients with extended disease SCLC (ED-SCLC) compared to those with limited disease SCLC (LD-SCLC). In LD-SCLC, patients with poor PS lived for a significantly shorter time than patients with good PS (HR: 7.791, p = 0.0001); however, BMI (HR: 1.035, p = 0.8), WL (HR: 0.857, p = 0.5), and ALB (HR: 0.743, p = 0.3) had no significant effect on the outcome. In ED-SCLC, PS (HR: 4.257, p = 0.0001), WL (HR: 1.677, p = 0.001), and ALB (HR: 0.680, p = 0.007) had an impact on survival, but BMI did not (HR: 0.791, p = 0.08). In LD-SCLC, the univariate analysis showed that only poor PS was correlated with increased mortality (HR: 7.791, p = 0.0001); yet it lost significance in multivariate analysis. In ED-SCLC, poor PS (HR: 4.257, p = 0.0001), WL (HR: 1.667, p = 0.001), and a low ALB level (HR: 0.680, p = 0.007) were shown to be factors for poor prognosis in the univariate analysis; yet only PS remained significant in multivariate analysis (HR: 2.286, p = 0.001).
Conclusion: Even though BMI and serum albumin showed no prognostic value in SCLC patients treated with chemotherapy, PS was found to be the most significant prognostic factor in both LD- and ED-SCLC stages.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
